Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes.
Sign Up to like & getrecommendations! Published in 2021 at "Dalton transactions"
DOI: 10.1039/d1dt02763h
Abstract: α-N-Heterocyclic thiosemicarbazones such as triapine and COTI-2 are currently investigated as anticancer therapeutics in clinical trials. However, triapine was widely inactive against solid tumor types. A likely explanation is the short plasma half-life time and… read more here.
Keywords: anticancer copper; copper; formulations anticancer; drug ... See more keywords
DDDR-81. A Ribonucleotide Reductase Targeted Strategy Enhances Radiosensitivity in Breast Cancer Brain Metastases via Triapine
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0718
Abstract: Breast cancer brain metastases (BCBM) are a frequent and devastating complication of advanced disease, particularly in triple-negative breast cancer (TNBC), where standard therapies such as whole-brain radiotherapy (WBRT) offer limited benefit due to dose-limiting toxicity… read more here.
Keywords: breast cancer; triapine; brain metastases;
Abstract CT194: ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct194
Abstract: Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitization. ETCTN… read more here.
Keywords: lutetium 177; dotatate; 177 dotatate; triapine ... See more keywords